Page 1

EX - 99.1 2 a52368387ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2021 - Revenue of $ 1.61 Billion Increases 89.3 % , 86.5 % in Constant Currency - - Organic Revenue Increases 107.0 % , 104.0 % in Constant Currency - - Company Posts GAAP Diluted EPS of $ 2.50 , Non - GAAP Diluted EPS of $ 2.86 – MARLBOROUGH , Mass .-- ( BUSINESS WIRE ) -- January 27 , 2021 -- Hologic , Inc. ( Nasdaq : HOLX ) announced today the Company's financial results for the fiscal first quarter ended December 26 , 2020 . " Hologic had a strong start to fiscal 2021 across all our businesses and major geographies , " said Steve MacMillan , the Company's Chairman , President and Chief Executive Officer . “ Our Diagnostics division continued to deliver incredible performance by making a massive impact against COVID - 19 . Furthermore , our Breast Health and Surgical businesses continued to strengthen , with each returning to growth in the United States , Europe and Asia - Pacific . " Recent Highlights • • • • • Revenue increased 89.3 % for the quarter , or 86.5 % in constant currency , including revenue from the divested Medical Aesthetics business in the prior year period . Excluding material acquisitions and divestitures , organic revenue in the first quarter increased 107.0 % , or 104.0 % in constant currency . Worldwide molecular diagnostics revenue of $ 995.3 million increased 457.6 % , or 448.7 % in constant currency , exceeding expectations based on increased production of , and strong global demand for , the Company's two SARS - CoV - 2 assays that run on the fully automated Panther® and Panther Fusion® systems . In early January , announced an agreement to acquire Biotheranostics , a privately held , commercial - stage company that provides molecular diagnostic tests for breast and metastatic cancers , for approximately $ 230 million . On December 31 , completed the acquisition of SOMATEX Medical Technologies GmbH , a leader in biopsy site markers and localization technologies , for approximately $ 64 million . Recent regulatory clearances : 。 U.S. FDA clearance of Genius AI ™ detection technology , a deep learning - based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images . 。 U.S. FDA approval of a diagnostic claim for the Company's Aptima® HIV - 1 Quant Dx viral load monitoring assay , making it the first dual - claim assay for both diagnosis and viral load monitoring in the United States . 。 European CE Mark of the Genius ™ digital diagnostics system , the first digital cytology platform to combine a new artificial intelligence algorithm with advanced digital imaging to help identify cancerous and pre - cancerous cells in women . • Cash flow from operations was $ 650.0 million in the quarter . Based on this strong cash flow , the Company announced the Biotheranostics and SOMATEX acquisitions , repaid $ 250 million of debt under its revolving credit facility , and repurchased 1.5 million shares of its common stock for $ 101 million . Key financial results for the fiscal first quarter are shown in the table below . Revenues Gross Margin Operating Expenses Operating Margin Net Margin Diluted EPS GAAP Non - GAAP Q1'21 $ 1,609.8 Change Increase Q1'20 ( Decrease ) $ 850.5 Change 89.3 % Q1'21 $ 1,609.8 Q1'20 $ 850.5 Increase ( Decrease ) 89.3 % 73.3 % 51.0 % 2,230 bps 77.2 % 61.6 % 1,560 bps $ 294.9 $ 309.0 ( 4.6 % ) $ 274.5 $ 289.3 ( 5.1 % ) 55.0 % 14.7 % 4,030 bps 60.2 % 27.5 % 3,270 bps 40.6 % 45.4 % ( 480 bps ) 46.6 % 19.3 % 2,730 bps $ 2.50 $ 1.43 74.8 % $ 2.86 $ 0.61 368.9 % Throughout this press release , all dollar figures are in millions , except EPS , unless otherwise noted . Some totals may not foot due to rounding . Unless otherwise noted , all results are compared to the corresponding prior year period . Non - GAAP results exclude certain cash and non - cash items as discussed under “ Use of Non - GAAP Financial Measures . ” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period . Organic revenue is on a constant currency basis and excludes the divested Blood Screening and Medical Aesthetics businesses , as well as the acquired Acessa business .